PTC Therapeutics received a positive opinion from a European regulator in May for its Duchenne muscular dystrophy (DMD) treatment Translarna and conditional approval in Europe is expected this summer, said the company's CFO Shane Kovacs. Kovacs said the company, which has seen its shares nearly double in price since the May announcement, is currently enrolling a large-scale, placebo-controlled, confirmatory Phase 3 trial for Translarna in nonsense mutation DMD. Furthermore, he said PTC initiated a confirmatory Phase 3 study of Translarna in nonsense mutation cystic fibrosis.

If you liked this article you might like

Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter

Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

No Good Stock Left Behind: Cramer's 'Mad Money' Recap (Tuesday 7/25/17)

No Good Stock Left Behind: Cramer's 'Mad Money' Recap (Tuesday 7/25/17)

Hertz Global Holdings, Honeywell, PetMed Express, Allergan: 'Mad Money' Lightning Round

Hertz Global Holdings, Honeywell, PetMed Express, Allergan: 'Mad Money' Lightning Round

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms